[8-K] Atara Biotherapeutics, Inc Reports Material Event

Rhea-AI Filing Summary

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) filed a Form 8-K dated July 14, 2025 reporting two material events.

• Item 2.02 – Results of Operations and Financial Condition: The Company released a preliminary estimate of its cash, cash equivalents and short-term investments as of June 30, 2025. No dollar amount was disclosed and management cautions that the figure is subject to change when full second-quarter results are issued.
• Item 8.01 – Other Events: A press release titled “Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)” was furnished as Exhibit 99.1 and incorporated by reference. Specific regulatory or business details are not included in the 8-K text.

The filing contains no detailed financial statements, earnings figures, or transactional information. Investors will need to review the forthcoming Form 10-Q and Exhibit 99.1 for quantitative data and substantive regulatory updates.

Insights

Financial Analyst

TL;DR: Neutral 8-K; only a preliminary cash snapshot and notice of Tab-cel regulatory update—no numbers, no guidance.

The filing serves mainly as a placeholder, signaling that management has sufficient visibility to reference its liquidity position and to highlight forthcoming regulatory news on Tabelecleucel. However, the absence of the actual cash figure or any qualitative insight into the regulatory pathway limits immediate valuation impact. Materiality will depend on the undisclosed cash balance and the substance of the press release in Exhibit 99.1, which is not included here. As presented, the disclosure is routine and informational without market-moving detail.

false 0001604464 0001604464 2025-07-14 2025-07-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 14, 2025

Atara Biotherapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-36548		46-0920988
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2380 Conejo Spectrum Street Suite 200
Thousand Oaks, California		91320
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (805) 623-4211

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ATRA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

In connection with the press release described in Item 8.01 below, on July 14, 2025, Atara Biotherapeutics, Inc. (the “Company”) announced the Company’s cash, cash equivalents and short-term investments as of June 30, 2025. The preliminary estimate is based on currently available information and does not present all necessary information for a complete understanding of the Company’s financial condition as of June 30, 2025 or the Company’s results of operations for the second quarter ended June 30, 2025.

Item 8.01 Other Events.

On July 14, 2025, the Company issued a press release titled “Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®).” A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.		Description
99.1		Press release, dated July 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						ATARA BIOTHERAPEUTICS, INC.
Date: July 14, 2025				By:		/s/ AnhCo Nguyen Ph.D.
						AnhCo Nguyen, Ph.D.
						President and Chief Executive Officer

FAQ

What form did Atara Biotherapeutics (ATRA) file on July 14, 2025?

The company filed a Form 8-K current report with the U.S. Securities and Exchange Commission.

Which items are addressed in the ATRA Form 8-K?

The report covers Item 2.02 (preliminary cash estimate) and Item 8.01 (regulatory & business updates on Tabelecleucel).

Did Atara disclose its exact cash balance for June 30, 2025?

No. The 8-K states a preliminary cash, cash equivalents and short-term investments figure but does not provide the amount.

What exhibit accompanies the 8-K filing?

Exhibit 99.1 is a press release titled “Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®).”

Where is Atara Biotherapeutics’ stock listed and what is its ticker?

Atara’s common stock trades on The Nasdaq Stock Market LLC under the symbol ATRA.